MAPT and Alzheimer disease: We analyzed plasma Aβ40, Aβ42, and P-Tau concentrations in the AD, aMCI, and NC groups, and found that with the progression of the disease, plasma Aβ40, Aβ42, and P-Tau in the three groups showed upward trends, which was consistent with the findings of Yang et al. (2018) and Zecca et al. (2018).